Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route
Štěpán Vyskočil, David Cardin, Jeffrey P. Ciavarri, Joe Conlon, Courtney Cullis, Dylan B. England, Rachel E. Gershman, Kenneth M. Gigstad, Krista Gipson, Alexandra E. Gould, Paul D. Greenspan, Robert Griffin, Nanda K. Gulavita, Sean Harrison, Zhigen Hu, Yongbo Hu, Akito Hata, Jian Huang, Shih‐Chung Huang, Dave Janowick, Matthew R. Jones, Vihren N. Kolev, Steven Langston, Hong Myung Lee, Gang Li, David Lok, Li‐Ting Ma, Doanh Mai, Jenna Malley, Atsushi Matsuda, Hirotake Mizutani, Miho Mizutani, Nina Molchanova, Elise Nunes, Sandeep Pusalkar, Christelle Renou, Scott Rowland, Yosuke Sato, Michael H. Shaw, Luhua Shen, Zhan Shi, R.J. Skene, François Soucy, Steve Stroud, He N. Xu, Tianlin Xu, Adnan O. Abu‐Yousif, Ji Zhang
Abstract
leads to an acute innate immune response as measured by cytokine secretion and adaptive immune response via activation of CD8+ cytotoxic T-cells, which ultimately provides robust antitumor efficacy.